112 related articles for article (PubMed ID: 25472854)
1. The Triple-Negative Breast Cancer Database: an omics platform for reference, integration and analysis of triple-negative breast cancer data.
Raju R; Paul AM; Asokachandran V; George B; Radhamony L; Vinaykumar M; Girijadevi R; Pillai MR
Breast Cancer Res; 2014 Dec; 16(6):490. PubMed ID: 25472854
[TBL] [Abstract][Full Text] [Related]
2. Triple negative breast cancer: a multi-omics network discovery strategy for candidate targets and driving pathways.
Karagoz K; Sinha R; Arga KY
OMICS; 2015 Feb; 19(2):115-30. PubMed ID: 25611337
[TBL] [Abstract][Full Text] [Related]
3. High-throughput «Omics» technologies: New tools for the study of triple-negative breast cancer.
Judes G; Rifaï K; Daures M; Dubois L; Bignon YJ; Penault-Llorca F; Bernard-Gallon D
Cancer Lett; 2016 Nov; 382(1):77-85. PubMed ID: 26965997
[TBL] [Abstract][Full Text] [Related]
4. MicroRNAs as regulatory elements in triple negative breast cancer.
Gyparaki MT; Basdra EK; Papavassiliou AG
Cancer Lett; 2014 Nov; 354(1):1-4. PubMed ID: 25107641
[TBL] [Abstract][Full Text] [Related]
5. microRNA-200c downregulates XIAP expression to suppress proliferation and promote apoptosis of triple-negative breast cancer cells.
Ren Y; Han X; Yu K; Sun S; Zhen L; Li Z; Wang S
Mol Med Rep; 2014 Jul; 10(1):315-21. PubMed ID: 24821285
[TBL] [Abstract][Full Text] [Related]
6. Elucidation of epithelial-mesenchymal transition-related pathways in a triple-negative breast cancer cell line model by multi-omics interactome analysis.
Pauling JK; Christensen AG; Batra R; Alcaraz N; Barbosa E; Larsen MR; Beck HC; Leth-Larsen R; Azevedo V; Ditzel HJ; Baumbach J
Integr Biol (Camb); 2014 Nov; 6(11):1058-68. PubMed ID: 25124678
[TBL] [Abstract][Full Text] [Related]
7. L1CAM is expressed in triple-negative breast cancers and is inversely correlated with androgen receptor.
Doberstein K; Milde-Langosch K; Bretz NP; Schirmer U; Harari A; Witzel I; Ben-Arie A; Hubalek M; Müller-Holzner E; Reinold S; Zeimet AG; Altevogt P; Fogel M
BMC Cancer; 2014 Dec; 14():958. PubMed ID: 25510351
[TBL] [Abstract][Full Text] [Related]
8. Combined Label-Free Quantitative Proteomics and microRNA Expression Analysis of Breast Cancer Unravel Molecular Differences with Clinical Implications.
Gámez-Pozo A; Berges-Soria J; Arevalillo JM; Nanni P; López-Vacas R; Navarro H; Grossmann J; Castaneda CA; Main P; Díaz-Almirón M; Espinosa E; Ciruelos E; Fresno Vara JÁ
Cancer Res; 2015 Jun; 75(11):2243-53. PubMed ID: 25883093
[TBL] [Abstract][Full Text] [Related]
9. MicroRNAs-mediated cell fate in triple negative breast cancers.
Sui X; Wang X; Han W; Li D; Xu Y; Lou F; Zhou J; Gu X; Zhu J; Zhang C; Pan H
Cancer Lett; 2015 May; 361(1):8-12. PubMed ID: 25748387
[TBL] [Abstract][Full Text] [Related]
10. The proteomic landscape of triple-negative breast cancer.
Lawrence RT; Perez EM; Hernández D; Miller CP; Haas KM; Irie HY; Lee SI; Blau CA; Villén J
Cell Rep; 2015 Apr; 11(4):630-44. PubMed ID: 25892236
[TBL] [Abstract][Full Text] [Related]
11. Applications of RNA Indexes for Precision Oncology in Breast Cancer.
Ma L; Liang Z; Zhou H; Qu L
Genomics Proteomics Bioinformatics; 2018 Apr; 16(2):108-119. PubMed ID: 29753129
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide profiling of AP-1-regulated transcription provides insights into the invasiveness of triple-negative breast cancer.
Zhao C; Qiao Y; Jonsson P; Wang J; Xu L; Rouhi P; Sinha I; Cao Y; Williams C; Dahlman-Wright K
Cancer Res; 2014 Jul; 74(14):3983-94. PubMed ID: 24830720
[TBL] [Abstract][Full Text] [Related]
13. Another review on triple negative breast cancer. Are we on the right way towards the exit from the labyrinth?
Chiorean R; Braicu C; Berindan-Neagoe I
Breast; 2013 Dec; 22(6):1026-33. PubMed ID: 24063766
[TBL] [Abstract][Full Text] [Related]
14. Crucial and novel cancer drivers in a mouse model of triple-negative breast cancer.
Johnson JP; Kumar P; Koulnis M; Patel M; Simin K
Cancer Genomics Proteomics; 2014; 11(3):115-26. PubMed ID: 24969692
[TBL] [Abstract][Full Text] [Related]
15. Proteome-centric cross-omics characterization and integrated network analyses of triple-negative breast cancer.
Gong TQ; Jiang YZ; Shao C; Peng WT; Liu MW; Li DQ; Zhang BY; Du P; Huang Y; Li FF; Li MY; Han ZL; Jin X; Ma D; Xiao Y; Yang PY; Qin J; Shao ZM; Zhu W
Cell Rep; 2022 Mar; 38(9):110460. PubMed ID: 35235781
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications.
Asleh K; Riaz N; Nielsen TO
J Exp Clin Cancer Res; 2022 Sep; 41(1):265. PubMed ID: 36050786
[TBL] [Abstract][Full Text] [Related]
17. Subtyping of breast cancer using reverse phase protein arrays.
Sonntag J; Schlüter K; Bernhardt S; Korf U
Expert Rev Proteomics; 2014 Dec; 11(6):757-70. PubMed ID: 25400094
[TBL] [Abstract][Full Text] [Related]
18. Identification of dysregulated microRNAs in triple-negative breast cancer (review).
Yang F; Zhang W; Shen Y; Guan X
Int J Oncol; 2015 Mar; 46(3):927-32. PubMed ID: 25571912
[TBL] [Abstract][Full Text] [Related]
19. Shotgun proteomics of archival triple-negative breast cancer samples.
Gámez-Pozo A; Ferrer NI; Ciruelos E; López-Vacas R; Martínez FG; Espinosa E; Vara JÁ
Proteomics Clin Appl; 2013 Apr; 7(3-4):283-91. PubMed ID: 23436753
[TBL] [Abstract][Full Text] [Related]
20. Integrated analysis of expression profiling data identifies three genes in correlation with poor prognosis of triple-negative breast cancer.
Zhang C; Han Y; Huang H; Min L; Qu L; Shou C
Int J Oncol; 2014 Jun; 44(6):2025-33. PubMed ID: 24676531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
